Ixazomib Citrate - National Cancer Institute

Ixazomib Citrate - National Cancer Institute













New Drug for Multiple Myeloma

A new summary about the drug ixazomib citrate. It was recently approved by the Food and Drug Administration (FDA) to treat multiple myeloma in patients who have already received at least one other treatment.

Ixazomib Citrate

• 
• 
• 
• 
• 
• 
• 

listen (ik-SA-zoh-mib SIH-trayt)

This page contains brief information about ixazomib citrate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Ninlaro

FDA Approved

Yes

FDA Approval for Ixazomib Citrate

Use in Cancer

Ixazomib citrate is approved to be used with lenalidomide and dexamethasone to treat:

• Multiple myeloma in patients who have already received at least one other type of treatment.

Ixazomib citrate is also being studied in the treatment of other types of cancer.

More About Ixazomib Citrate

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Targeted Cancer Therapies - Information about the use of this drug to treat cancer.

Clinical Trials Accepting Patients

Find Clinical Trials for Ixazomib Citrate - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.